Ratings ResMed Inc. Australian S.E.

Equities

RMD

AU000000RMD6

Market Closed - Australian S.E. Other stock markets 02:10:24 2024-07-12 am EDT			5-day change	1st Jan Change
29.9 ^AUD	+4.36%		+4.84%	+17.53%

Jul. 01	ResMed Inc.(NYSE:RMD) added to Russell 1000 Dynamic Index	CI
Jul. 01	ResMed Inc.(NYSE:RMD) added to Russell Midcap Value Index	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
The company is in a robust financial situation considering its net cash and margin position.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Over the past four months, analysts' average price target has been revised upwards significantly.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

With an expected P/E ratio at 29.52 and 24.82 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
RESMED INC.	+17.53%	30.09B	-
THERMO FISHER SCIENTIFIC	+3.26%	209B	B
DANAHER CORPORATION	+6.55%	183B	B-
INTUITIVE SURGICAL, INC.	+31.66%	158B	B-
BOSTON SCIENTIFIC CORPORATION	+34.32%	114B	A-
SIEMENS HEALTHINEERS AG	+5.13%	67.29B	A-
EDWARDS LIFESCIENCES CORPORATION	+19.33%	54.83B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.30%	46.88B	B+
AGILENT TECHNOLOGIES, INC.	-4.84%	38.58B	A
GE HEALTHCARE TECHNOLOGIES INC.	+3.83%	36.65B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes